Figure 1.

The ESR1 gene and most common mutations [reprinted with permission—Ma et al. (1)]. A schematic diagram of estrogen receptor-α (ERα) mutations and their frequencies in ER+ metastatic breast cancer after therapy with aromatase inhibitors and other endocrine agents. The structural domains of ERα are shown, including the transcription activation function 1 (AF1) domain, the DNA-binding domain (DBD), the receptor dimerization and nuclear localization (hinge) domain, and the ligand-binding domain (LBD), and AF2 domain.